BMO Capital Upgrades Biomarin Pharmaceutical to Outperform, Announces $102 Price Target
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Kostas Biliouris has upgraded Biomarin Pharmaceutical (NASDAQ:BMRN) from Market Perform to Outperform and set a price target of $102.
July 05, 2023 | 9:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical has been upgraded to Outperform by BMO Capital, with a new price target of $102.
The upgrade from Market Perform to Outperform by BMO Capital indicates a positive outlook for Biomarin Pharmaceutical. The new price target of $102 also suggests potential upside for the stock. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100